Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1 1

Status

Completed 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Sarcoma 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Neoplasms 2Carcinoma, Ovarian Epithelial 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Multiple Myeloma 1Melanoma 1Lung Cancer - Malignant Pleural Mesothelioma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Hemangiosarcoma 1Esophagogastric Cancer 1Esophageal Neoplasms 1Disorders of Sex Development 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × STA 9090 × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01560416 2026-03-03

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
50 enrolled 14 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02060253 2018-06-14

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
9 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02637375 2016-05-30

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

University of Chicago

Phase NA Withdrawn
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01273896 2015-11-20

Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
22 enrolled 6 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡